Immunis strives to provide transformative solutions to age-related diseases through the emerging sector of secretome therapeutics. The goal is to optimize cellular secretomes to provide maximal benefits for several indications of disease. Dr. Keirstead’s presentation will highlight Immunis’ ongoing Phase 1/2a clinical trial investigating the secretome as a therapeutic for elderly adults with muscle atrophy associated with knee osteoarthritis.
Immunis is dedicated to driving advancements in biomedicine. We invite you to join us at BIO to push the scientific boundaries and ensure the best human health outcomes for all.
About BIO International Convention
The BIO International Convention represents the largest global event for biotech, offering networking, partnership opportunities, and insights from key industry leaders. For more information, please visit: https://www.bio.org/events/bio-international-convention
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.